在心力衰竭患者中,低剂量托尔瓦普坦可能改善肝功能
Yasuaki Mino1, Kohei Hoshikawa1, Takafumi Naito2
1Department of Hospital Pharmacy and Hamamatsu University School of Medicine, 1-20-1 Handayama, Chuo-ku, Hamamatsu 431-3192, Japan.
Toxicology reports
|April 14, 2025
概括
低剂量托尔瓦普坦在心力衰竭患者中没有引起肝损伤. 托尔瓦普坦及其代谢物的药理动力学可能会改善肝功能,显示肝功能可能得到改善.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肝病学 肝病学是一种肝病学.
- 心脏病学 心脏病学
背景情况:
- 心力衰竭患者经常经历肝脏功能障碍.
- 托尔瓦普坦是一种用于心力衰竭管理的血管压素V2受体对手.
- 了解托尔瓦普坦对肝功能的影响对于患者的安全至关重要.
研究的目的:
- 研究心力衰竭患者中托尔瓦普坦药理动力学和肝损伤标志物之间的关系.
- 用肝功能测试来评估托尔瓦普坦及其代谢物 (DM-4103,DM-4107) 之间的相关性.
- 为了评估托尔瓦普坦对肝细胞损伤和胆固醇形成标志物的作用.
主要方法:
- 在51名日本心力衰竭患者中,对托尔瓦普坦和代谢物的血度进行LC-MS/MS分析.
- 评估药物度与肝酶 (AST,ALT),NT-proBNP和胆固醇酶标记物 (CP-I,CP-III) 之间的相关性.
- 评估肝损伤标志物 (K18,谷氨酸脱酶).
主要成果:
- 托尔瓦普坦,DM-4103和DM-4107的中位数度分别为16.2,287和38.0 ng/mL.
- 托尔瓦普坦给药后,AST,ALT和T-Bil水平显著下降,并且与托尔瓦普坦度负相关.
- AST与DM-4107有负相关; CP-III与DM-4103有正相关,而CP-I与DM-4103有负相关. 没有发现与K18和谷氨酸脱酶的相关性.
结论:
- 低剂量托尔瓦普坦在这个患者队列中没有诱导肝损伤.
- 托尔瓦普坦的药理动力学可能与心力衰竭患者肝功能改善有关.
- 需要进一步的研究来阐明托尔瓦普坦潜在的肝保护作用背后的机制.
更多相关视频
07:24Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.2K
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.8K
相关概念视频
01:22Heart Failure Drugs: Diuretics
294
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
294
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
407
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
407
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278
01:26Heart Failure Drugs: Inotropic Agents
424
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
424
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.1K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.1K